Delivery Order SPE2DB20D9127-SPE2DB24FPPB1

Award Date 10/13/23
Potential Completion Date 10/16/23
Potential Value $7.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,571.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of the pharmaceutical product Nucala 100 mg/ml auto-injector. This order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, that covers a wide range of pharmaceutical items to support...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,571.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, which is part of a larger $499,999,999 indefinite delivery contract (IDC) with DMS Pharmaceutical Group, is for the supply of Nucala 100 mg/mL auto-injectors to support the recurring medical supply needs of military health facilities worldwide. DMS...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,892.90 contract, with a completion date of April 16, 2024, is to provide the DLA's Medical Supply Chain division with 100 mg/mL Nucala auto-injectors. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued up to $499,999,999, that allows the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order worth $17,036.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order falls under a larger single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which covers a wide range of pharmaceutical products and medical supplies to support the...
The U.S. government agency, the Defense Logistics Agency (DLA), has awarded a firm fixed-price delivery order contract worth $7,571.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of NUCALA 100 MG/ML AUTO-INJECTORML and has a period of performance through May 3, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order worth $106,002.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order, placed under the DLA's SPE2DB Indefinite Delivery Contract (IDC), is for the delivery of NUCALA 100 MG/ML auto-injectors to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant IDC with the DLA, valued...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a $3,785.80 firm fixed-price delivery order for Nucala 100 mg/mL auto-injectors, with a completion date of September 13, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $11,357.40 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of Nucala 100 mg/mL auto-injectors and has an ultimate completion date of July 26, 2023. DMS Pharmaceutical Group Inc. is an established federal contractor that specializes in providing a wide range of pharmaceutical products and medical supplies to military...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $5,678.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Nucala 100 mg/mL syringes and has a completion date of December 4, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $5,678.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 100 mg/mL Nucala auto-injectors and has an ultimate completion date of December 10, 2024. This order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) under the SPE2DB program, which enables the DLA to issue...
  • SPE2DB20D9127
    Indefinite Delivery Contract
  • SPE2DB20D9127-SPE2DB24FPPB1
    Delivery Order

The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $7,571.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Nucala 100 mg/mL auto-injectors to support the recurring medical supply needs of military healthcare facilities.

DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This contract award is not associated with a specific set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains. The contract has an ultimate completion date of October 16, 2023.

Generated 2/27/25, 1:17 PM